Acutaas Chemicals Ltd Q4 FY2023 Concall Summary

Key Takeaways

• Pharma-led 19% revenue growth, margins recovered: FY23 revenue crossed INR621 crores, driven by 22% core pharma growth, while EBITDA margins rebounded from 18% in Q1 to 21.9% in Q4 after a cost-pressured first half.
• Electrolyte additives hit commercial inflection: Six global customer approvals secured, plant-scale trial orders received, and a bigger commercial order expected this quarter, with two next-generation molecules advancing through validation.
• Baba Fine Chemicals acquisition opens semiconductor vertical: The 55% stake brings PPT-purity chemistry and a photo-resistance chemicals franchise that management expects to grow 3-4x in a year, with 40+ products ready for global promotion.
• Specialty chemicals turnaround is underway but early: Margins improved to 10% after eight quarters of stabilization, with 4-5 new molecules commercializing in FY24 and a target of 18-19% operating margin this year.
• What to watch next quarter: Whether the promised bigger electrolyte commercial order materializes, the pace of specialty margin expansion toward the 200 bps target, and initial revenue contribution from Baba Fine Chemicals.

Pharma Intermediates: The Core Engine

• Volume-driven growth with margin recovery: FY23 pharma revenue grew 22% year-on-year entirely on volume as prices remained suppressed, which also held back top-line growth by roughly 2%.
• Cost pressures rationalized: The year began with war-driven spikes in commodity and gas prices that compressed margins to 18% in Q1; by Q4, margins recovered to 21.9%, matching the FY21 pharma margin target.
• Demand revival underway: Management saw a gradual upswing in H2 FY23 and expects the revival to continue through H1 FY24, with a buffer of at least 1-1.5 quarters of visibility to sustain the pharma growth rate.
• Anticoagulant portfolio fully built out: The company has developed intermediates for apixaban, rivaroxaban, edoxaban and betrixaban, with process patents held for the first two and expiry protection through 2035; over 26 customers worldwide are qualified for apixaban alone.
• Chinese competition is not a threat to this business: Management argues the company never benefited from China plant shutdowns during COVID and remains the global market leader in key products, with China in second or third spot, so the Chinese chemical industry revival has minimal bearing.

Naresh Patel: "We never benefited from the shutting up plants in China due to COVID or supply chain issues. And second most important thing is that we remain a global market leader in our key products, with China and other geographies in the second and third spot. So Chinese industry coming back strongly will not affect us."

The Fermion CDMO Relationship

• Contract scope expanded materially: The company added two high-value intermediates to its existing Fermion engagement, taking the total to three advanced intermediates and increasing the contract value manyfold.
• End-product demand is surging: The underlying product, darolutamide, is growing at 200-300x annually; Fermion's volume expectations for 2026 were already met in 2023, and its basic API manufacturing plant is fully utilized.
• Supply exclusivity locked in: Fermion currently makes the intermediate in-house and has no alternative source; management stated the intermediate supply will be 100% with Ami Organics and Fermion only.
• CDMO economics apply: The work involves development followed by manufacturing, placing it in the company's CDMO segment; management declined to disclose revenue potential citing Fermion's status as a public company.

Naresh Patel: "This product is growing unexpectedly to 200 or 300x a year. Whatever they expected in 2026, they already closed in 2023."

Electrolyte Additives: The Battery Chemicals Bet

• Commercial validation achieved: Six customers worldwide have approved the company's electrolyte additives, plant-scale trial orders of a few metric tons have been received, and a bigger commercial order is expected during the current quarter.
• Product pipeline expanded to four molecules: Two mature products (VCB and FEC) are in the commercializing stage, while two new molecules, one a liquid additive for lithium-ion battery capacity and one for solid-state batteries, have cleared lab-scale approval and are in advanced validation.
• Geopolitical tailwind is structural: US and European customers have stopped buying battery cells or components sourced from China, creating a direct advantage for Indian manufacturers; all nine customers outside India fall into this dynamic.
• Capacity expansion being planned: The company has started work on capacity expansion plans and expects to incur that capex in H2 FY24, with details to be announced once finalized; revenues are expected by H1 FY24, with invoicing possible this quarter or next.

Naresh Patel: "The advantage for Ami Organics or, say, for Indian manufacturer, is that the U.S. and other European countries have stopped buying any battery cells or anything which is generated from China."

Specialty Chemicals: The Margin Turnaround Story

• A year of consolidation, now shifting to growth: FY23 was spent on product sustainability, technology upgradation for methyl salicylate and parabens, and developing 4-5 new molecules that will commercialize in FY24 across UV absorbers, agrochemicals and petrochemicals.
• Margins rebuilt from zero to 10%: The specialty chemicals business sustained operating margins at 10% for eight consecutive quarters after starting from zero, with the most recent quarter adding another 100 basis points.
• Targeting 18-19% operating margin this year: Management expects 50-100 bps of quarter-on-quarter improvement, driven by a mix of technology upgrades, volume growth and new product introductions; the total improvement could exceed 200 bps.
• Revenue ambition is 2.5x in 2-3 years: This is a projection, not formal guidance, and rests on the new molecules gaining commercial traction; 20 molecules have been developed in Gujarat Organics, with some already under LOIs and customer qualification.
• In-house raw material integration adds margin levers: Three raw materials previously imported from China are now manufactured and consumed in-house, providing an additional advantage to both revenue and profitability.

Baba Fine Chemicals: The Semiconductor Entry

• Acquired 55% stake for INR68 crores: The deal was structured with minimal cash outlay, paid via preference shares; the remaining 45% is held by a key third-party partner who will stay involved, and 45% of PAT will be booked under minority interest.
• PPT-purity chemistry is the moat: Baba Fine Chemicals manufactures photo-resistance chemicals for the semiconductor industry at parts-per-trillion purity, a capability management describes as unique; the business was founded and run by three scientist-entrepreneurs holding multiple patents.
• Growth trajectory is aggressive: Management expects the business to grow more than 3-4x in a year based on current orders in hand, with a fourfold top-line expansion still the stated target; margins currently exceed 60% but are expected to moderate roughly 10% as volumes scale and new segments involve higher energy consumption.
• 40+ products ready for global markets: The company has historically manufactured exclusively for one customer but has already developed over 40 products with samples available; promotion has begun in Japan, Korea and other markets.

Naresh Patel: "Baba Fine Chem has a main application in photo resistance chemical in semiconductor industries and they are making very high purity chemicals, Part per trillion kind of purity PPT. Normally, we talk in PPM. So that is a very unique technology and capability of Baba Fine Chem."

Capex, Cash Flow & Balance Sheet

• FY24 capex guided at INR200-220 crores: This includes the brownfield Ankleshwar facility (operational by December 2024), INR35 crores of maintenance capex, and additional solar investment; electrolyte additives capex will be incremental and back-half loaded.
• Working capital improved materially: The company released INR40-45 crores of cash from inventory, bringing the working capital cycle down to 108 days, with a further target to reduce receivable days by another 10.
• Cash flow expected to remain robust: Management believes operating cash flow will support both routine opex and the planned capex program through the coming year.
• Flow reactors driving efficiency: Multipurpose flow reactors now handle 11 reactions in diazotization, 9 in nitration and 20 in esterification, improving operating efficiency while minimizing effluent generation and energy consumption; the pipeline includes 2-3 new reactions like n-butyllithium and Grignard.

Guidance & Commitments

Key Metrics